Evaluation of Quality of Life Indicators of Patients with Arterial Hypertension and Comorbid Chronic Obstructive Pulmonary Disease

Iryna Vysochyna; Tetiana Burtniak

doi:doi:10.11648/j.ijcems.20220802.11

| Peer-Reviewed

Evaluation of Quality of Life Indicators of Patients with Arterial Hypertension and Comorbid Chronic Obstructive Pulmonary Disease

Iryna Vysochyna, Tetiana Burtniak

Published in International Journal of Clinical and Experimental Medical Sciences (Volume 8, Issue 2)

Received: 2 March 2022 Accepted: 21 March 2022 Published: 20 April 2022

Views: Downloads:

Download PDF

Share This Article

Twitter
Linked In
Facebook

Abstract

The purpose of this study to analyze the quality of life (QoL) of patients in accordance with a personalized approach in the complex drug treatment of patients with hypertension and comorbid chronic obstructive pulmonary disease (COPD). Materials and methods: the analysis of two groups of male patients. The presence of left ventricular remodeling with preserved ejection fraction (≥ 50%) – Group 1 with antihypertensive therapy of valsartan with amlodipine, or mid-range (45-49%) – Group 2 with combination of candesartan and nebivolol. The general clinical examination was performed using international clinical scales and validated SF-36 and SGRQ questionnaires. Comparison of QoL parameters according to the SF-36 questionnaire revealed a significant difference between pre- and post-treatment parameters in Groups 1 and 2 (p <0.05). In conclusion, a comprehensive approach is recommended in patients with hypertension and comorbid COPD, which provide long-term antihypertensive and bronchodilator effects and are recommended for use in patients. After 6 months of comprehensive combination therapy, the condition of patients has significantly improved, as evidenced by changes in QoL according to the SF-36 and SGRQ questionnaires. All indicators of mental and physical components of the SF-36 questionnaire significantly increased and the values of the categories of the specific respiratory questionnaire SGRQ decreased.

Published in	International Journal of Clinical and Experimental Medical Sciences (Volume 8, Issue 2)
DOI	10.11648/j.ijcems.20220802.11
Page(s)	20-23
Creative Commons	This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.
Copyright	Copyright © The Author(s), 2022. Published by Science Publishing Group

Keywords

Quality of Life, Arterial Hypertension, Chronic Obstructive Pulmonary Disease, Antihypertensive Therapy

References

[1]	Наказ МОЗ України від 24.05.2012 № 384 «Про затвердження та впровадження медико-технологічних документів зі стандартизації медичної допомоги при артеріальній гіпертензії» (2012) (1) Order of the Ministry of Health of Ukraine dated 24.05.2012 № 384 "On approval and implementation of medical and technological documents for standardization of medical care for hypertension"] https://zakon.rada.gov.ua/rada/show/v0384282-12#Text
[2]	Borghi C, Tubach F, De Backer G, Dallongeville J, Guallar E, Medina J, et al. (2016). Lack of control of hypertension in primary cardiovascular disease prevention in Europe: Results from the EURIKA study. Int J Cardiol. Sep 1; 218: 83–8.
[3]	Бондарчук СА. (2018). Вибір між фіксованими комбінаціями блокаторів ренін-ангіотензин-альдостеронової системи з антагоністом кальцію: що обрати? [Choosing between fixed combinations of renin-angiotensin-aldosterone system blockers with a calcium antagonist: what to choose?] Ліки України; 3 (36): 4–10.
[4]	Guidelines for the management of arterial hypertension ESC/ESH. (2018). Eur Heart J., 39 (33): 3021–104.
[5]	Адашева ТВ, Бабак СЛ, Горбунова МВ, Задионченко ВС, Зыков КА, Кароли НА, Ли ВВ, Ребров АП. (2017). Национальные клинические рекомендации: диагностика и лечение пациентов с хронической обструктивной болезнью легких и артериальной гипертензией. [Інтернет] [National clinical guidelines: diagnosis and treatment of patients with chronic obstructive pulmonary disease and hypertension] https://www.rnmot.ru/public/uploads/RNMOT/clinical/2017/ХОБЛ_и_АГ_Малявин_250618.pdf
[6]	Артериальная гипертензия у взрослых. Профессиональные ассоциации. (2020). Клин. рек. Москва: Российское кардиологическое общество; [Hypertension in adults. Professional associations] Доступно: http://webmed.irkutsk.ru/doc/pdf/fedhypert.pdf
[7]	Burtniak TZ, Potabashniy VA, Fesenko VI. (2019). Application of combined therapy in hospital patients with arterial hypertension and comorbid chronic obstructive pulmonary disease. East European Scientific J., 10 (50); 2: 19–23.
[8]	Буртняк ТЗ, Потабашній ВА. (2018). Аналіз прихильності до лікування пацієнтів з АГ у поєднанні з ХОЗЛ. [Analysis of adherence to treatment of patients with hypertension in combination with COPD] Укр. кардіол. журнал. Вер 26-28; Київ: ТОВ «МОРІОН», 2018; 1: 9–10.
[9]	Ambrosino I, Gallone MS, Patano F, Giannico OV, Barbagelata E, Gnerre P, et al. (2019). Gender differences in chronic obstructive pulmonary disease: an analysis of hospitalization indicators. ITJM. 13 (1): 38–44. DOI: https://doi.org/10.4081/itjm.2019.1099
[10]	Albertson TE, Bowman WS, Harper RW, Godbout RM, Murin S. (2019). Evidence-based review of data on the combination inhaler umeclidinium/vilanterol in patients with COPD. Int J Chron Obstruct Pulmon Dis., 14: 1251–65.
[11]	Puxxedu E, Ora J, Calzetta L, Cazzola M. (2017). Progress and prospects for long-acting β2-agonists in the treatment of COPD. Вестн. соврем. клин. медицины. 10 (1): 7–14. DOI: 10.20969/VSKM.2017.10(1).
[12]	Samp JC, Joo MJ, Schumock GT, Calip GS, Pickard AS, Lee TA. (2017). Risk of Cardiovascular and Cerebrovascular Events in COPD Patients Treated With Long-Acting β2-Agonist Combined With a Long-Acting Muscarinic or Inhaled Corticosteroid. Ann Pharmacother. Nov; 51 (11): 945–53. DOI: 10.1177/1060028017719716
[13]	Scott LJ, Hair P. (2014). Umeclidinium/Vilanterol: First Global Approval. Drugs. 74: 389–95.
[14]	McDonagh MA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, Burri H, Butler J, Čelutkienė J, Chioncel O, Cleland JGF, Coats AJS, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Muneretto C, Piepoli MF, Price S, Rosano GMC, Ruschitzka F, Skibelund AK. (2021). ESC Scientific Document Group. 2021. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. European Heart Journal. Volume 42, Issue 36, 21 September 2021, Pages 3599–3726, https://doi.org/10.1093/eurheartj/ehab368
[15]	Наказ МОЗ України від 27.06.2013 № 555. (2013). Про затвердження та впровадження медико-технологічних документів зі стандартизації медичної допомоги при хронічному обструктивному захворюванні легень [Internet]. [About the statement and introduction of medical and technological documents on standardization of medical care at chronic obstructive pulmonary disease]. https://ips.ligazakon.net/document/view/moz20082.

Cite This Article

Plain Text BibTeX RIS

APA Style

Iryna Vysochyna, Tetiana Burtniak. (2022). Evaluation of Quality of Life Indicators of Patients with Arterial Hypertension and Comorbid Chronic Obstructive Pulmonary Disease. International Journal of Clinical and Experimental Medical Sciences, 8(2), 20-23. https://doi.org/10.11648/j.ijcems.20220802.11

Copy | Download

ACS Style

Iryna Vysochyna; Tetiana Burtniak. Evaluation of Quality of Life Indicators of Patients with Arterial Hypertension and Comorbid Chronic Obstructive Pulmonary Disease. Int. J. Clin. Exp. Med. Sci. 2022, 8(2), 20-23. doi: 10.11648/j.ijcems.20220802.11

Copy | Download

AMA Style

Iryna Vysochyna, Tetiana Burtniak. Evaluation of Quality of Life Indicators of Patients with Arterial Hypertension and Comorbid Chronic Obstructive Pulmonary Disease. Int J Clin Exp Med Sci. 2022;8(2):20-23. doi: 10.11648/j.ijcems.20220802.11

Copy | Download

@article{10.11648/j.ijcems.20220802.11,
  author = {Iryna Vysochyna and Tetiana Burtniak},
  title = {Evaluation of Quality of Life Indicators of Patients with Arterial Hypertension and Comorbid Chronic Obstructive Pulmonary Disease},
  journal = {International Journal of Clinical and Experimental Medical Sciences},
  volume = {8},
  number = {2},
  pages = {20-23},
  doi = {10.11648/j.ijcems.20220802.11},
  url = {https://doi.org/10.11648/j.ijcems.20220802.11},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ijcems.20220802.11},
  abstract = {The purpose of this study to analyze the quality of life (QoL) of patients in accordance with a personalized approach in the complex drug treatment of patients with hypertension and comorbid chronic obstructive pulmonary disease (COPD). Materials and methods: the analysis of two groups of male patients. The presence of left ventricular remodeling with preserved ejection fraction (≥ 50%) – Group 1 with antihypertensive therapy of valsartan with amlodipine, or mid-range (45-49%) – Group 2 with combination of candesartan and nebivolol. The general clinical examination was performed using international clinical scales and validated SF-36 and SGRQ questionnaires. Comparison of QoL parameters according to the SF-36 questionnaire revealed a significant difference between pre- and post-treatment parameters in Groups 1 and 2 (p <0.05). In conclusion, a comprehensive approach is recommended in patients with hypertension and comorbid COPD, which provide long-term antihypertensive and bronchodilator effects and are recommended for use in patients. After 6 months of comprehensive combination therapy, the condition of patients has significantly improved, as evidenced by changes in QoL according to the SF-36 and SGRQ questionnaires. All indicators of mental and physical components of the SF-36 questionnaire significantly increased and the values of the categories of the specific respiratory questionnaire SGRQ decreased.},
 year = {2022}
}

Copy | Download

TY  - JOUR
T1  - Evaluation of Quality of Life Indicators of Patients with Arterial Hypertension and Comorbid Chronic Obstructive Pulmonary Disease
AU  - Iryna Vysochyna
AU  - Tetiana Burtniak
Y1  - 2022/04/20
PY  - 2022
N1  - https://doi.org/10.11648/j.ijcems.20220802.11
DO  - 10.11648/j.ijcems.20220802.11
T2  - International Journal of Clinical and Experimental Medical Sciences
JF  - International Journal of Clinical and Experimental Medical Sciences
JO  - International Journal of Clinical and Experimental Medical Sciences
SP  - 20
EP  - 23
PB  - Science Publishing Group
SN  - 2469-8032
UR  - https://doi.org/10.11648/j.ijcems.20220802.11
AB  - The purpose of this study to analyze the quality of life (QoL) of patients in accordance with a personalized approach in the complex drug treatment of patients with hypertension and comorbid chronic obstructive pulmonary disease (COPD). Materials and methods: the analysis of two groups of male patients. The presence of left ventricular remodeling with preserved ejection fraction (≥ 50%) – Group 1 with antihypertensive therapy of valsartan with amlodipine, or mid-range (45-49%) – Group 2 with combination of candesartan and nebivolol. The general clinical examination was performed using international clinical scales and validated SF-36 and SGRQ questionnaires. Comparison of QoL parameters according to the SF-36 questionnaire revealed a significant difference between pre- and post-treatment parameters in Groups 1 and 2 (p <0.05). In conclusion, a comprehensive approach is recommended in patients with hypertension and comorbid COPD, which provide long-term antihypertensive and bronchodilator effects and are recommended for use in patients. After 6 months of comprehensive combination therapy, the condition of patients has significantly improved, as evidenced by changes in QoL according to the SF-36 and SGRQ questionnaires. All indicators of mental and physical components of the SF-36 questionnaire significantly increased and the values of the categories of the specific respiratory questionnaire SGRQ decreased.
VL  - 8
IS  - 2
ER  -

Copy | Download

Author Information

Iryna Vysochyna

Department of Family Medicine FPE, Dnipro State Medical University, Dnipro, Ukraine
Tetiana Burtniak

Department of Family Medicine FPE, Dnipro State Medical University, Dnipro, Ukraine

Download PDF

Sections

Plain Text BibTeX RIS

APA Style

Iryna Vysochyna, Tetiana Burtniak. (2022). Evaluation of Quality of Life Indicators of Patients with Arterial Hypertension and Comorbid Chronic Obstructive Pulmonary Disease. International Journal of Clinical and Experimental Medical Sciences, 8(2), 20-23. https://doi.org/10.11648/j.ijcems.20220802.11

Copy | Download

ACS Style

Iryna Vysochyna; Tetiana Burtniak. Evaluation of Quality of Life Indicators of Patients with Arterial Hypertension and Comorbid Chronic Obstructive Pulmonary Disease. Int. J. Clin. Exp. Med. Sci. 2022, 8(2), 20-23. doi: 10.11648/j.ijcems.20220802.11

Copy | Download

AMA Style

Iryna Vysochyna, Tetiana Burtniak. Evaluation of Quality of Life Indicators of Patients with Arterial Hypertension and Comorbid Chronic Obstructive Pulmonary Disease. Int J Clin Exp Med Sci. 2022;8(2):20-23. doi: 10.11648/j.ijcems.20220802.11

Copy | Download

@article{10.11648/j.ijcems.20220802.11,
  author = {Iryna Vysochyna and Tetiana Burtniak},
  title = {Evaluation of Quality of Life Indicators of Patients with Arterial Hypertension and Comorbid Chronic Obstructive Pulmonary Disease},
  journal = {International Journal of Clinical and Experimental Medical Sciences},
  volume = {8},
  number = {2},
  pages = {20-23},
  doi = {10.11648/j.ijcems.20220802.11},
  url = {https://doi.org/10.11648/j.ijcems.20220802.11},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ijcems.20220802.11},
  abstract = {The purpose of this study to analyze the quality of life (QoL) of patients in accordance with a personalized approach in the complex drug treatment of patients with hypertension and comorbid chronic obstructive pulmonary disease (COPD). Materials and methods: the analysis of two groups of male patients. The presence of left ventricular remodeling with preserved ejection fraction (≥ 50%) – Group 1 with antihypertensive therapy of valsartan with amlodipine, or mid-range (45-49%) – Group 2 with combination of candesartan and nebivolol. The general clinical examination was performed using international clinical scales and validated SF-36 and SGRQ questionnaires. Comparison of QoL parameters according to the SF-36 questionnaire revealed a significant difference between pre- and post-treatment parameters in Groups 1 and 2 (p <0.05). In conclusion, a comprehensive approach is recommended in patients with hypertension and comorbid COPD, which provide long-term antihypertensive and bronchodilator effects and are recommended for use in patients. After 6 months of comprehensive combination therapy, the condition of patients has significantly improved, as evidenced by changes in QoL according to the SF-36 and SGRQ questionnaires. All indicators of mental and physical components of the SF-36 questionnaire significantly increased and the values of the categories of the specific respiratory questionnaire SGRQ decreased.},
 year = {2022}
}

Copy | Download

TY  - JOUR
T1  - Evaluation of Quality of Life Indicators of Patients with Arterial Hypertension and Comorbid Chronic Obstructive Pulmonary Disease
AU  - Iryna Vysochyna
AU  - Tetiana Burtniak
Y1  - 2022/04/20
PY  - 2022
N1  - https://doi.org/10.11648/j.ijcems.20220802.11
DO  - 10.11648/j.ijcems.20220802.11
T2  - International Journal of Clinical and Experimental Medical Sciences
JF  - International Journal of Clinical and Experimental Medical Sciences
JO  - International Journal of Clinical and Experimental Medical Sciences
SP  - 20
EP  - 23
PB  - Science Publishing Group
SN  - 2469-8032
UR  - https://doi.org/10.11648/j.ijcems.20220802.11
AB  - The purpose of this study to analyze the quality of life (QoL) of patients in accordance with a personalized approach in the complex drug treatment of patients with hypertension and comorbid chronic obstructive pulmonary disease (COPD). Materials and methods: the analysis of two groups of male patients. The presence of left ventricular remodeling with preserved ejection fraction (≥ 50%) – Group 1 with antihypertensive therapy of valsartan with amlodipine, or mid-range (45-49%) – Group 2 with combination of candesartan and nebivolol. The general clinical examination was performed using international clinical scales and validated SF-36 and SGRQ questionnaires. Comparison of QoL parameters according to the SF-36 questionnaire revealed a significant difference between pre- and post-treatment parameters in Groups 1 and 2 (p <0.05). In conclusion, a comprehensive approach is recommended in patients with hypertension and comorbid COPD, which provide long-term antihypertensive and bronchodilator effects and are recommended for use in patients. After 6 months of comprehensive combination therapy, the condition of patients has significantly improved, as evidenced by changes in QoL according to the SF-36 and SGRQ questionnaires. All indicators of mental and physical components of the SF-36 questionnaire significantly increased and the values of the categories of the specific respiratory questionnaire SGRQ decreased.
VL  - 8
IS  - 2
ER  -

Copy | Download